Cargando…

The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study

AIM: This study examined the real-world effectiveness and safety outcomes of vedolizumab in ulcerative colitis (UC) patients who had failed anti-tumor necrosis factor (anti-TNF) therapy in Korea. METHODS: A retrospective chart review study was conducted in adults with moderate to severely active UC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Byong Duk, Cheon, Jae Hee, Song, Ki Hwan, Kim, Joo Sung, Kim, Young-Ho, Yoon, Hyuk, Lee, Kang-Moon, Kang, Sang-Bum, Jang, Byung Ik, Park, Jae Jun, Kim, Tae Oh, Lee, Dae-Wook, Foo, Chee Yoong, Shin, Jeong Eun, Park, Dong Il
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261845/ https://www.ncbi.nlm.nih.gov/pubmed/34285716 http://dx.doi.org/10.1177/17562848211024769

Ejemplares similares

Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
por: Moon, Jung Rock, et al.
Publicado: (2020)

Corrigendum: Unmet Psychosocial Needs of Patients Newly Diagnosed with Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
por: Moon, Jung Rock, et al.
Publicado: (2021)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea
por: Yoon, Hyuk, et al.
Publicado: (2023)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
por: Seo, Hyun Il, et al.
Publicado: (2014)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Cytomegalovirus Colitis in a Patient With Ulcerative Colitis on Vedolizumab Monotherapy
por: Meeralam, Yaser, et al.
Publicado: (2023)

Clinical Characteristics and Long-term Outcomes of Pediatric Ulcerative Colitis: A Single-Center Experience in Korea
por: Jang, Jooyoung, et al.
Publicado: (2022)

Is Clostridium difficile infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea
por: Kim, Dae Bum, et al.
Publicado: (2018)

Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use
por: Kang, Ho Suk, et al.
Publicado: (2019)

Long-Term Outcomes of Cytomegalovirus Reactivation in Patients with Moderate to Severe Ulcerative Colitis: A Multicenter Study
por: Kim, You Sun, et al.
Publicado: (2014)

Prognostic Value of Terminal Ileal Inflammation in Patients with Ulcerative Colitis
por: Yu, Jongwook, et al.
Publicado: (2021)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
por: Kothari, Megha, et al.
Publicado: (2015)

Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
por: Subhaharan, Deloshaan, et al.
Publicado: (2022)

Elevated risk of cervical cancer in elderly women with incident ulcerative colitis in South Korea
por: Kim, Jihoon, et al.
Publicado: (2023)

Recurrent Mesalazine-Induced Myopericarditis in a Patient with Ulcerative Colitis
por: Park, Eun Hye, et al.
Publicado: (2012)

Assessment of disease activity by fecal immunochemical test in ulcerative colitis
por: Ryu, Dae Gon, et al.
Publicado: (2016)

A case of ulcerative colitis presenting with cerebral venous thrombosis
por: Lee, Junghwan, et al.
Publicado: (2018)

Clinical course of ulcerative colitis patients who develop acute pancreatitis
por: Kim, Jong Wook, et al.
Publicado: (2017)

PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab
por: Kim, Min Kyu, et al.
Publicado: (2023)

Short-term Outcomes of Elective 2-Stage Restorative Proctocolectomy for Ulcerative Colitis in Korea: Does Laparoscopy Have Benefits?
por: Bong, Jun Woo, et al.
Publicado: (2020)

Quality of Life in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: Changes in the MOSAIK Cohort Over 1 Year
por: Jo, Ik Hyun, et al.
Publicado: (2022)

Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
por: Kim, Kyuwon, et al.
Publicado: (2022)

Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis
por: Lee, Sun-Ho, et al.
Publicado: (2017)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

New and emerging treatments for ulcerative colitis: a focus on vedolizumab
por: Gledhill, Tamsin, et al.
Publicado: (2013)

Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
por: Singh, Amrinder, et al.
Publicado: (2022)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
por: Yu, Jongwook, et al.
Publicado: (2022)

Clinical Characteristics and Long-term Prognosis of Elderly-Onset Ulcerative Colitis in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea
por: Park, Sang Hyoung, et al.
Publicado: (2021)

Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis
por: Ryu, Dae Gon, et al.
Publicado: (2019)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
por: Schäffler, Holger, et al.
Publicado: (2017)

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
por: Dart, Robin J, et al.
Publicado: (2017)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
por: Narula, Neeraj, et al.
Publicado: (2019)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
por: Gonzalez-Vivo, Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nj2vr3dra69biibp6cjdajnc0l